Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Eli Lilly and CompanyNYSE: LLY
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin widens to 54.2%
Operating margin was 54.2% in Q2 FY2026, up 9.1 pp from a year earlier. On a trailing-twelve-month basis it was 49.7%, up 7.6 pp year over year. Over 3 fiscal years it widened by 15.2 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 18 analysts of 41.5% for the fiscal year ending Dec 2026, down from 45.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 54.2%+4.8 pp QoQ
- Last fiscal yearDec 2025
- 45.6%+7.7 pp YoY
- LTMJun 2026
- 49.7%+7.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.1 pp | -19.5 pp | -28.6 pp |
| 1 year | +7.7 pp | -4.1 pp | -11.8 pp |
| 3 years | +15.2 pp | +5.6 pp | -9.6 pp |
| 5 years | +9.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 45.6%
- Year-over-year change
- +7.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.6% | +7.7pp |
| FY2024 | 2024-12-31 | 37.8% | +6.2pp |
| FY2023 | 2023-12-31 | 31.6% | +1.3pp |
| FY2022 | 2022-12-31 | 30.3% | +2.3pp |
| FY2021 | 2021-12-31 | 28.0% | — |
Operating Margin vs competitors
How LLY compares with its peers on the latest reported figures
- LLY's LTM Jun 2026 operating margin of 49.7% is the highest of the 10 companies compared; the peer median is 26.7%.
- Its year-over-year change of +7.6 pp is the 3rd highest of 10, against a peer median of +0.3 pp.
- Over three fiscal years its change of +15.2 pp compares with a peer median of +0.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 49.7% | +7.6 pp | +15.2 pp | |
| LTM Jun 2026 | 43.1% | -2.6 pp | -1.0 pp | |
| LTM Sep 2026 | 35.5% | +20.4 pp | +1.6 pp | |
| LTM Jun 2026 | 33.2% | +9.7 pp | -7.3 pp | |
| LTM Jun 2026 | 30.5% | +0.3 pp | +12.9 pp | |
| LTM Jun 2026 | 26.7% | +0.6 pp | -9.9 pp | |
| LTM Sep 2026 | 25.7% | -0.4 pp | +0.9 pp | |
| LTM Sep 2026 | 23.7% | +1.6 pp | +14.9 pp | |
| LTM Jun 2026 | 16.7% | -16.9 pp | +5.3 pp | |
| LTM Jun 2026 | 14.8% | -3.6 pp | -4.5 pp | |
| Peer median (excluding LLY) | 26.7% | +0.3 pp | +0.9 pp | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 11.05B |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Research & Development | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Selling, General & Admin | 6.14B | 6.07B | 6.94B | 8.59B | 11.09B |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.59B | 24.43B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| EBITDA | 8.04B | 8.66B | 8.57B | 18.81B | 31.69B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.04B | 29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% |
| Interest Income | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M |
| Interest Expense | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M |
| Other Income / Expenses | (1.78B) | (1.85B) | (4.23B) | (4.36B) | (3.97B) |
| Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Pre-Tax Margin | 21.7% | 23.8% | 19.2% | 28.2% | 39.5% |
| Income Tax Expense | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Basic) | 5.85 | 6.57 | 5.83 | 11.76 | 23.07 |
| EPS (Diluted) | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 |
| Weighted Avg Shares | 953.65M | 950.18M | 899.38M | 900.61M | 898M |
| Weighted Avg Shares (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898M |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.